Table 3.
Baseline characteristics of patients with IPA (proven, probable, or possible).
| SARS-CoV-2(+) (n: 108) | SARS-CoV-2(-) (n: 32) | p | |
|---|---|---|---|
| Age (years ± SD) | 65.5 (±12.1) | 69.4 (±14.2) | 0.18 |
| Gender (male) | 64.80% | 40.00% | 0.02 |
| Tracheobronchitis | 10.7% (3/28) | 11.1% (2/18) | 0.89 |
| Hemoptysis | 11.10% | 12.50% | 0.76 |
| Proven or probable invasive aspergillosis | 22.20% | 68.80% | <0.001 |
| Type of pulmonary infiltrate | |||
| -No infiltrate | 1.90% | 6.20% | 0.22 |
| -Bilateral, ground-glass opacities | 81.50% | 53.10% | 0.002 |
| -Nodular infiltrate | 2.80% | 31.20% | <0.001 |
| -Caveat | 1.90% | 9.40% | 0.08 |
| -Pulmonary embolism | 12.00% | 0 | 0.04 |
| -Pleural fluid | 34.30% | 21.90% | 0.34 |
| Diabetes | 27.80% | 23.30% | 0.81 |
| Diabetes (insulin required) | 2.80% | 0 | 1 |
| Renal insufficiency (chronic) | 11.10% | 10.00% | 1 |
| Renal insufficiency (acute or chronic) | 37.00% | 28.10% | 0.4 |
| Hepatic insufficiency (chronic) | 3.70% | 3.30% | 1 |
| Hepatic insufficiency (acute or chronic) | 13.00% | 3.30% | 0.19 |
| Active hematologic disorder | 4.60% | 20.00% | 0.014 |
| Progenitor hematologic transplant | 0.90% | 10% | 0.032 |
| Solid organ transplant | 0.90% | 3.30% | 0.38 |
| Active chemotherapy (solid tumor) | 1.90% | 20.00% | 0.001 |
| Corticoid therapy | 7.40% | 20.00% | 0.08 |
| Corticoid therapy (>15 mg prednisone/d) | 3.70% | 6.70% | 0.61 |
| Therapy including biologics | 1.90% | 6.70% | 0.2 |
| Neutrophils <100/µL (last 3 months) | 0.90% | 3.10% | 0.4 |
| Neutrophils count (±SD) | 8800 (±6200) | 6500 (±5400) | 0.06 |
| Lymphocytes count (±SD) | 1094 (±912) | 2061 (±2500) | 0.049 |
| Platelets count (±SD) | 231 × 103 (±104 × 103) | 197 × 103 (±108 × 103) | 0.13 |
| D-Dimer count (±SD) | 6600 (±13,100) | - | - |
| IL-6 (±SD) | 227 (±740) | - | - |
| CRP (±SD) | 88.3 (±87.2) | 75.8 (±5400) | 0.53 |
| Previous aspergillosis | 0 | 6.20% | 0.05 |
| Oxygen any requirements | 98.10% | 56.20% | <0.001 |
| Oxygen high requirements | 85.20% | 12.50% | <0.001 |
| ICU admission | 78.70% | 12.50% | <0.001 |
| Mechanical ventilation | 73.10% | 9.40% | <0.001 |
| Inotropic therapy | 63.00% | 9.40% | <0.001 |
| Pronation required | 62.00% | 3.10% | <0.001 |
| ECMO | 0.90% | 0 | 0.54 |
| ICU days | 25 (±19) | 26 (±17) | 0.91 |
| Previous corticoid therapy (any dose) | 95.40% | 43.80% | <0.001 |
| Previous corticoid therapy (>250 mg/d) | 4.60% | 0 | 0.59 |
| Bacterial infection | 90.70% | 75.00% | 0.03 |
| CMV infection | 38.20% | 87.70% | 0.03 |
| CMV disease | 10.90% | 28.60% | 0.22 |
| Remdesivir therapy | 23.40% | 0 | 0.001 |
| Tocilizumab therapy | 29.00% | 0 | <0.001 |
| Initial Aspergillosis therapy | |||
| -Voriconazole | 23.10% | 25.00% | 0.89 |
| -Isavuconazole | 24.10% | 6.20% | 0.03 |
| -Liposomal Amphotericin B | 7.40% | 6.20% | 0.82 |
| Hospitalization total days | 35 (±25) | 14 (±17) | <0.001 |
| ICU total days | 20 (±20) | 3.6 (±11) | <0.001 |
| Dead | 40.70% | 25.00% | 0.14 |
| Related mortality | 17.60% | 9.40% | 0.16 |
ECMO: extracorporeal membrane oxygenation. IL-6: Interleukin-6. CMV: Cytomegalovirus. RCP: reactive C Protein. ICU: Intensive care unit.